These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25834023)

  • 1. Avastin and Lucentis: a guide through the legal maze.
    Lock D
    BMJ; 2015 Apr; 350():h1377. PubMed ID: 25834023
    [No Abstract]   [Full Text] [Related]  

  • 2. Why have UK doctors been deterred from prescribing Avastin?
    Cohen D
    BMJ; 2015 Apr; 350():h1654. PubMed ID: 25834024
    [No Abstract]   [Full Text] [Related]  

  • 3. Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.
    Torjesen I
    BMJ; 2013 Jul; 347():f4678. PubMed ID: 23881948
    [No Abstract]   [Full Text] [Related]  

  • 4. A licence to cure.
    Aronson JK; Ferner RE
    BMJ; 2015 Apr; 350():h1723. PubMed ID: 25834026
    [No Abstract]   [Full Text] [Related]  

  • 5. Novartis takes legal action over trusts' advice to use bevacizumab for wet AMD.
    Torjesen I
    BMJ; 2012 Apr; 344():e2959. PubMed ID: 22532011
    [No Abstract]   [Full Text] [Related]  

  • 6. Legal. PCTs taken to court over use of cheaper drug.
    Calkin S
    Health Serv J; 2012 Apr; 122(6303):10-1. PubMed ID: 22741353
    [No Abstract]   [Full Text] [Related]  

  • 7. Why using Avastin for eye disease is so difficult.
    Torjesen I
    BMJ; 2012 May; 344():e3012. PubMed ID: 22549057
    [No Abstract]   [Full Text] [Related]  

  • 8. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
    Hawkes N
    BMJ; 2012 May; 344():e3275. PubMed ID: 22573655
    [No Abstract]   [Full Text] [Related]  

  • 9. Primary care trusts reverse advice to ophthalmologists to use cheaper drug for wet age related macular degeneration.
    Hawkes N
    BMJ; 2012 Jul; 345():e5161. PubMed ID: 22846417
    [No Abstract]   [Full Text] [Related]  

  • 10. The off-label use of medication: the latest on the Avastin - Lucentis debacle.
    Jansen RM
    Med Law; 2013 Mar; 32(1):65-77. PubMed ID: 23781765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GMC is criticised for refusing to disclose reasons behind its advice to support prescribing for Lucentis rather than Avastin for wet AMD.
    Cohen D
    BMJ; 2015 Apr; 350():h1981. PubMed ID: 25869865
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost comparison of ranibizumab and bevacizumab.
    Jackson TL; Kirkpatrick L
    BMJ; 2011 Aug; 343():d5058. PubMed ID: 21862536
    [No Abstract]   [Full Text] [Related]  

  • 13. Perhaps the Avastin debate should be resolved in court.
    Fell G
    BMJ; 2015 Apr; 350():h2044. PubMed ID: 25901019
    [No Abstract]   [Full Text] [Related]  

  • 14. The GMC's stance on Avastin.
    Dickson N
    BMJ; 2015 Apr; 350():h2043. PubMed ID: 25898987
    [No Abstract]   [Full Text] [Related]  

  • 15. [Avastin-Lucentis: off-label and surroundings].
    Messori A
    Recenti Prog Med; 2014 Apr; 105(4):137-40. PubMed ID: 24770536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minister rules out use of Avastin over Lucentis for wet AMD.
    Kmietowicz Z
    BMJ; 2015 Apr; 350():h2050. PubMed ID: 25882175
    [No Abstract]   [Full Text] [Related]  

  • 17. CCGs face legal threat for offering off-label drug for wet AMD.
    Cohen D
    BMJ; 2017 Oct; 359():j5021. PubMed ID: 29089307
    [No Abstract]   [Full Text] [Related]  

  • 18. Ask the doctor. I have wet macular degeneration. I am trying to decide between Avastin and Lucentis. Which drug is better?
    Heier JS
    Harv Health Lett; 2011 Dec; 37(2):6-7. PubMed ID: 27024308
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration.
    Kent JS; Iordanous Y; Mao A; Powell AM; Kent SS; Sheidow TG
    Can J Ophthalmol; 2012 Apr; 47(2):159-64. PubMed ID: 22560422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attacks on publicly funded trials: what happens when industry does not want to know the answer.
    Cohen D
    BMJ; 2015 Apr; 350():h1701. PubMed ID: 25834025
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.